HUBBARD, Ohio, Aug. 1, 2012 /PRNewswire/ -- NanoLogix (OTC
Markets: NNLX), a biotechnology innovator in the rapid detection
and identification of live-threat bacteria, is featured today in
the USA Today Group B Strep (GBS) Awareness Campaign titled Your
guide to Group B Strep. The campaign featured in the
USA Today News Section promotes
public education on the dangers of GBS in newborns and highlights
the latest testing methods to help prevent the disease.
Research using NanoLogix BNF technology, from the University of Texas Health Science Center in
Houston (UTHSC), is featured in the campaign. While
GBS culturing methods typically take 48 hours of incubation to
obtain results, this research from UTHSC documents that NanoLogix
technology can detect, identify and provide antibiotic sensitivity
results for GBS in as little as four hours, four times faster than
conventional methods.
(Photo: http://photos.prnewswire.com/prnh/20120613/CL23734)
"It's an honor to be included in this GBS awareness campaign,"
said NanoLogix CEO Bret
Barnhizer. "The strong readership of USA Today is a tremendous opportunity to help
pregnant women understand the dangers of Group B Strep and the
critical importance early testing plays in the health of their
newborns. We look forward to our rapid tests supporting the
protection of many newborns and mothers from this life-threatening
disease, both in the US and abroad."
According to Dr. James A.
McGregor, M.D.C.M of Group B Strep International,
"Untreated, Group B Streptococcus (GBS) infection is the most
common germ-related killer of newborn babies. More accurate,
rapid result tests for GBS can target use of antibiotic at birth
with possible reduction of resistance to antibiotics and help avoid
unnecessary disturbance of the healthy, protective bacteria inside
mother and baby. Parents appreciate doctors keeping Group B
Strep in mind to reduce possible infections before, during, and
after pregnancy. Accurate rapid testing when labor starts or
water breaks can help maximize protection from GBS infection for
babies at birth."
Marti Perhach, CEO/Cofounder of
Group B Strep International stated, "I first contacted NanoLogix
about a year ago when I heard they were developing a new rapid test
to detect Group B Strep. Having an accurate rapid test available is
extremely important, especially as women may test negative during
routine screening, but be positive during labor and delivery. Group
B Strep International's mission is to promote awareness and
prevention of Group B Strep disease in all babies throughout
pregnancy and early infancy. As sponsors of July as International
Group B Strep Awareness Month, we invited Nanologix to participate
in our awareness campaign. We are so appreciative of their efforts
in GBS awareness and the excellent information they have made
available to the general public through USAToday.com." For further
information on Group B Strep awareness and prevention, please visit
www.groupbstrepinternational.org.
If Group B Strep-colonized mothers give birth before antibiotics
can be administered, the bacteria can be passed to the newborn,
causing life-threatening infections, such as meningitis and sepsis.
According to the CDC, about 25 percent of women test positive
for Group B Strep and on average 1,200 American newborns less than
a week old contract the disease.
The 7-day campaign featured on USA Today.com will run until Monday August
6th. Also included in the GBS Awareness campaign are the
Centers for Disease Control and Prevention (CDC), the Keck School
of Medicine at the University of Southern California, the Center
for Vaccine Awareness & Research, and the Group B Strep
Association.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology and bioremediation,
microbial physiology, molecular biology, pharmacology,
pharmaco-kinetics, and antibiotic sensitivity. For more information
visit www.nanologix.com.
Media Contact:
Technica Communications
Lisa Ann Pinkerton
408-806-9626
Lisaann@technicacommunications.com
Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
carol@nanologix.com
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
SOURCE NanoLogix